StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) company profile

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.33+0.10 (+1.38%)

Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%

About Immunic

Pharmaceutical Preparations, SIC 2834

Immunic, Inc. is a clinical-stage biotechnology company focused on developing oral therapies for serious chronic inflammatory and autoimmune conditions, specifically targeting neurologic and gastrointestinal diseases. The company’s pipeline includes vidofludimus calcium, a small molecule candidate currently in Phase 3 clinical trials for relapsing multiple sclerosis. Its gastrointestinal program, IMU-856, targets epithelial regeneration and intestinal barrier restoration for disorders such as celiac disease and inflammatory bowel disease. Additionally, Immunic is advancing the preclinical IMU-381 program, which utilizes its Nurr1 platform for autoimmune indications. Immunic does not have commercial products, focusing its activities on clinical-stage patient populations with significant unmet medical needs.

The company operates internationally, maintaining headquarters in New York City and directing primary research and clinical operations from Gräfelfing, Germany. Further research facilities are situated in Martinsried and Halle/Saale, Germany, along with a subsidiary conducting development activities in Melbourne, Australia. Immunic employed 92 people as of February 2026.

Summary of the business section of Immunic's latest annual report, written by StockData.

Company profile

Company

Legal name
Immunic, Inc.
Founded
2016
Headquarters
New York, X1
Address
1200 Avenue Of The Americas, Suite 200 10036
Phone
(332) 255-9818
Website
imux.com
Employees
92, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, Minneapolis, MN

Stock & identifiers

Ticker
IMUX
Former tickers
VTL until Nov 7, 2019
Exchange
Nasdaq
IPO date
Apr 17, 2014
Shares outstanding
14M, Jul 31, 2026
Public float
$83.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Apr 27, 2026; 1-for-50 reverse, Aug 8, 2019; 1-for-40 reverse, Apr 15, 2019
SEC CIK
1280776
CUSIP
4525EP200
ISIN
US4525EP2001
FIGI
BBG001M75SX4
Share class FIGI
BBG001V10N36
LEI
549300R5T12FW5MEQB20
EIN
56-2358443

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Duane NashExecutive Chairman, Director45,256
Jason TardioPresident and COO12,512
Glenn WhaleyChief Financial Officer95,510
Erik LundgrenChief Executive Officer–
Michael A. PanzaraChief Medical Officer–
Andreas MuehlerChief Medical Officer582,466
Value Trading Fund OS LP BiotechnologyDirector427,629
Partners L. P/Il BvfDirector–
Value Fund L. P. BiotechnologyDirector–
Partners OS Ltd. BVFDirector–
Ii Gp Llc BvfDirector–
Robert Thorvald NagelDirector–
Value Fund Ii Lp BiotechnologyDirector–
I. Gp Llc BvfDirector–
Inc/Il BvfDirector–
Mark N. LampertDirector–
Gp Holdings Llc BvfDirector42,762
Elena RidloffDirector–
Jon CongletonDirector–
Richard Alan RudickDirector230,375
Barclay A. PhillipsDirector–
Joerg NeermannDirector200,000
Simona SkerjanecDirector–
Michael W. BonneyDirector–
Daniel VittDirector391,877

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Dr. Daniel Vitt
Chief Executive Officer
$625.25K$1.04M$401.26K$100.00K$2.30M-22%
Dr. Duane D. Nash
Former Executive Chairman
$400.55K$368.51K$162.00K–$979.88K-19%
Dr. Andreas Muehler
Former Chief Medical Officer
$540.13K$400.70K$252.27K$17.43K$1.26M-8%
Glenn Whaley
Chief Financial Officer
$463.75K$337.09K$218.50K–$1.06M-9%
Jason Tardio
COO and President
$512.50K$400.70K$239.20K–$1.20M+17%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 17, 2014
Offer price
$12.00
Securities offered
4,500,000
Gross proceeds
$54.00M
Exchange
Nasdaq
First trading day
Apr 17, 2014
First-day close
$12.000.0%
Lock-up ends (est.)
Oct 14, 2014

“The initial public offering price of our common stock is $12.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 1, 2026, we had 92 employees, nine of whom held M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?